Loading...
XNAS
ACAD
Market cap4.64bUSD
Dec 05, Last price  
27.44USD
1D
3.35%
1Q
8.63%
Jan 2017
-4.85%
IPO
315.13%
Name

ACADIA Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:ACAD chart
P/E
20.50
P/S
4.85
EPS
1.34
Div Yield, %
—
Shrs. gr., 5y
2.48%
Rev. gr., 5y
23.08%
Revenues
958m
+31.85%
10,956,3008,133,0007,555,0001,590,0006,399,00042,135,0002,067,0004,907,0001,145,000120,00061,00017,331,000124,901,000223,807,000339,076,000441,755,000484,145,000517,235,000726,437,000957,797,000
Net income
226m
P
-34,135,100-45,048,000-56,390,000-64,244,000-45,145,00015,139,000-22,765,000-20,849,000-37,948,000-92,475,000-164,443,000-271,393,000-289,403,000-245,192,000-235,259,000-281,584,000-167,870,000-215,975,000-61,286,000226,451,000
CFO
158m
+844.31%
-20,262,600-41,418,000-54,926,000-64,869,000-13,727,000-10,703,000-19,897,000-21,633,000-31,769,000-66,434,000-121,795,000-210,408,000-217,857,000-167,470,000-151,130,000-136,166,000-125,660,000-114,035,00016,702,000157,719,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
URL
https://acadia.com/
IPO date
May 27, 2004
Employees
540
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT